EN DE
STOCK COMPARISON

BioArctic AB (publ) vs Vertex Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how BioArctic AB (publ) (BIOA-B) and Vertex Pharmaceuticals (VRTX) compare, as of Sep 5, 2026.

As of Sep 5, 2026, Fair Value Calculator sees BioArctic AB (publ) as the less overvalued of the two: BioArctic AB (publ) trades at SEK 334 versus a fair value of SEK 273 (-18%), while Vertex Pharmaceuticals trades at $546 versus $279 (-49%).
BioArctic AB (publ)
BIOA-B.ST · SEK · Health Care
-18%
upside to fair value
overvalued
PriceSEK 334
Fair ValueSEK 273
Quality76/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-49%
upside to fair value
overvalued
Price$546
Fair Value$279
Quality79/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

BioArctic AB (publ)Vertex Pharmaceuticals
Valuation
145.6×P/E (TTM)28.8×
26.69×P/S (TTM)10.06×
15.56×P/B6.59×
22.7×EV/EBITDA23.8×
—PEG1.72×
−18.2%Fair value upside−49.0%
0.6%Dividend yield0.1%
SEK 2.00Dividend per share—
Profitability
46%Operating margin38%
—EBIT margin trend (5Y)0.86×
10%Return on equity24%
13%Return on assets12%
Growth
-66%Revenue growth (YoY)8%
106.1%Avg. growth/yr (3Y)10.6%
100.1%Avg. growth/yr (5Y)14.2%
+63.5%Value creation/yr+13.6%
Balance & size
36.1×Interest coverage (EBIT/interest)357.9×
—Debt / equity0.03×
$3BMarket cap$123B
mixedGrowth qualityhealthy

BioArctic AB (publ) leads: 8 to 5 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

BioArctic AB (publ)of which business quality 77 · market factors 57 Vertex Pharmaceuticalsof which business quality 77 · market factors 78
ProfitabilityMargins and returns on capital today
91
72
Quality GrowthAre margins and returns improving?
100
65
CashflowEarnings quality: real cash, not paper profit
65
79
Fin. StrengthBalance sheet, leverage, solvency risk
100
92
InvestmentDisciplined investing over empire-building
0
58
Low VolatilityCalm price path (market factor)
67
85
MomentumPrice trend over the last 3–12 months (market factor)
49
67
52W MomentumDistance to the 52-week high (market factor)
58
88
Net IssuanceBuybacks instead of dilution
80
82

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyBioArctic AB (publ)Price SEK 334Vertex PharmaceuticalsPrice $546
DCF Models+57%above the priceSEK 524-17%below the price$453
Earnings-Based+44%above the priceSEK 481-6%close to the price$516
Dividend Discountn/a-99%below the price$7.07
Multiples-41%below the priceSEK 197-49%below the price$278
Asset-Based-95%below the priceSEK 17.73-91%below the price$49.27
Growth DCF+85%above the priceSEK 619-36%below the price$348
Economic Profit-34%below the priceSEK 221-53%below the price$254
Growth Earnings+91%above the priceSEK 639+27%above the price$692
Minimum-95%below the priceSEK 17.73-99%below the price$7.07
Maximum+91%above the priceSEK 639+27%above the price$692
Median+44%above the priceSEK 481-43%below the price$313
Geometric mean-23%below the priceSEK 258-66%below the price$185

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

BioArctic AB (publ): 11 of 22 models see the stock below the current price.

Vertex Pharmaceuticals: 22 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

BioArctic AB (publ)
Bear SEK 208Fair Value SEK 273Bull SEK 831
SEK 334 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$546 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

BioArctic AB (publ) · Health Care

Quality score76 · Top 25%
Fair value upside-18% · above median

Vertex Pharmaceuticals · Health Care

Quality score79 · Top 25%
Fair value upside-49% · below median

Bottom line

As of Sep 5, 2026, Fair Value Calculator sees BioArctic AB (publ) as the less overvalued of the two: BioArctic AB (publ) trades at SEK 334 versus a fair value of SEK 273 (-18%), while Vertex Pharmaceuticals trades at $546 versus $279 (-49%).

Vertex Pharmaceuticals has the higher quality score (79/100).

See the full analysis →
BioArctic AB (publ) · Vertex Pharmaceuticals

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to BioArctic AB (publ)

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupMerck & Company vs UnitedHealth Group

Related to Vertex Pharmaceuticals

AstraZeneca vs UnitedHealth GroupThermo Fisher Scientific vs UnitedHealth GroupAmgen vs UnitedHealth GroupAbbott Laboratories vs UnitedHealth Group
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.